drugset / Trial / NCT00697710
A Phase Ib/IIa, Double-Blind, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of S-777469 in Subjects With Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this randomized, double-blind, placebo-controlled, sequential-cohort, dose-escalation study was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of S-777469, a CB2 cannabinoid receptor agonist, in subjects with mild to moderate atopic dermatitis.
Timeline
- Start
- 2007-07
- Primary completion
- 2008-02
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-777469 | Small molecule | 50 mg | — |
| Subject | S-777469 | Small molecule | 200 mg | — |
| Subject | S-777469 | Small molecule | 800 mg | — |